SpineGuard

Investors

Contact us

Investor Information

Stéphane Bette - Director, Co-Founder and Chief Executive Officer
Stéphane Bette,
Co founder and Deputy CEO
Pierre Jérôme,
Co founder, CEO & Chairman

Dear Shareholders,

We count on your participation in our General Assembly that will take place on June 8 th and we invite you to vote on the resolutions via internet or proxy without delay. Your vote is essential in order to gather the quorum and save the cost of a second call, approximately 20,000 euros. As a foreword to this important meeting for SpineGuard’s governance, we wish to come back to our greatest progress these last months and to share with you the main perspectives ahead of us.

Read the latest Financial News

Stock Information

Stock exchange information

  • ISIN code: FR0011464452
  • Stock Quote: ALSGD
  • Number of shares: 29.822.248
  • Sector: Medical technologies
  • Principal Index: Alternext All-share
  • Exchange: Euronext-Growth
  • Place of listing: Euronext Paris (France)
  • Eligibility to French PEA/SRD: Yes/No
  • Eligibility French PEA-PME: Yes

Financial agenda

  • 26 January 2022: 2021 Full-Year Sales
  • 27 January 2022: Investor Webinar
  • 28 April 2022: 2021 Full-Year Results
  • 28 April 2022: 2022 First-Quarter Sales
  • 8 June 2022: Annual Shareholders Meeting
  • 12 July 2022: 2022 First-Half Sales
  • 14 September 2022: 2022 First-Half Results
  • 12 October 2022: 2022 Third-Quarter Sales

Analysts

  • Biostrategic Research: Lionel Labourdette

Others

  • Liquidity contract: Tradition Securities And Futures (TSAF)
  • Auditors: Grant Thornton
  • Listing Sponsor: Swiss Life Banque Privée

Shareholders structure

(December 31th, 2021)

Stock quotes

  • To check the stock quote in real time, click here

For any request, don't hesitate to contact us

M